ATE311200T1 - Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten - Google Patents
Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonistenInfo
- Publication number
- ATE311200T1 ATE311200T1 AT01923433T AT01923433T ATE311200T1 AT E311200 T1 ATE311200 T1 AT E311200T1 AT 01923433 T AT01923433 T AT 01923433T AT 01923433 T AT01923433 T AT 01923433T AT E311200 T1 ATE311200 T1 AT E311200T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor antagonists
- compositions
- methods
- allergic conditions
- treating allergic
- Prior art date
Links
- 206010027654 Allergic conditions Diseases 0.000 title abstract 2
- 102000009389 Prostaglandin D receptors Human genes 0.000 title abstract 2
- 108050000258 Prostaglandin D receptors Proteins 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19664100P | 2000-04-12 | 2000-04-12 | |
| PCT/CA2001/000491 WO2001078697A2 (en) | 2000-04-12 | 2001-04-09 | Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE311200T1 true ATE311200T1 (de) | 2005-12-15 |
Family
ID=22726224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01923433T ATE311200T1 (de) | 2000-04-12 | 2001-04-09 | Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030055077A1 (de) |
| EP (1) | EP1274457B1 (de) |
| JP (1) | JP2003530426A (de) |
| AT (1) | ATE311200T1 (de) |
| AU (1) | AU2001250206A1 (de) |
| CA (1) | CA2405233A1 (de) |
| DE (1) | DE60115411D1 (de) |
| WO (1) | WO2001078697A2 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7217725B2 (en) * | 2000-09-14 | 2007-05-15 | Allergan, Inc. | Prostaglandin D2 antagonist |
| US7273883B2 (en) * | 2000-09-14 | 2007-09-25 | Allergan, Inc. | Prostaglandin EP4 antagonist |
| WO2004087095A2 (es) * | 2003-03-31 | 2004-10-14 | Osmotica Costa Rica, Sociedad Anonima | Dispositivo osmótico que contiene zafirlukast y un antagonista h1 |
| US7714132B2 (en) | 2004-03-11 | 2010-05-11 | Actelion Pharmaceuticals, Ltd. | Tetrahydropyridoindole derivatives |
| TW200716093A (en) * | 2005-04-28 | 2007-05-01 | Shionogi & Co | An antiasthmatic agent containing PGD2 receptor antagonist and leukotriene receptor antagonist |
| WO2007037187A1 (ja) | 2005-09-27 | 2007-04-05 | Shionogi & Co., Ltd. | Ｐｇｄ２受容体アンタゴニスト活性を有するスルホンアミド誘導体 |
| US8674115B2 (en) | 2009-12-23 | 2014-03-18 | Ironwood Pharmaceuticals, Inc. | CRTH2 modulators |
| AR080590A1 (es) | 2010-03-16 | 2012-04-18 | Aventis Pharma Inc | Pirimidinas sustituidas como antagonistas del receptor de la prostaglandina d2 |
| CA2793324A1 (en) | 2010-03-16 | 2011-09-22 | Aventis Pharmaceuticals Inc. | A substituted pyrimidine as a prostaglandin d2 receptor antagonist |
| US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| CA2790139C (en) | 2010-03-22 | 2018-03-13 | Actelion Pharmaceuticals Ltd | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators |
| WO2012003405A1 (en) | 2010-06-30 | 2012-01-05 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| US20130259830A1 (en) | 2010-07-12 | 2013-10-03 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| WO2012009137A1 (en) | 2010-07-12 | 2012-01-19 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| NZ609955A (en) | 2010-11-09 | 2015-05-29 | Ironwood Pharmaceuticals Inc | Sgc stimulators |
| JP5964945B2 (ja) | 2011-04-14 | 2016-08-03 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ７−（ヘテロアリ−ル−アミノ）−６，７，８，９−テトラヒドロピリド［１，２−ａ］インド−ル酢酸誘導体及びプロスタグランジンＤ２受容体調節剤としてのそれらの使用 |
| EP2762141A4 (de) * | 2011-09-29 | 2015-03-25 | Shionogi & Co | Arzneimittel zur behandlung von allergischer rhinitis mit einem pgd2-antagonisten und histamin-antagonisten |
| CN104066731B (zh) | 2011-12-27 | 2016-06-15 | 铁木医药有限公司 | 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类 |
| KR101418404B1 (ko) * | 2012-01-06 | 2014-07-10 | 한미약품 주식회사 | 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제 |
| US9309235B2 (en) | 2012-09-18 | 2016-04-12 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
| US9487508B2 (en) | 2012-09-19 | 2016-11-08 | Ironwood Pharmaceuticals, Inc. | SGC stimulators |
| SI2970243T1 (sl) | 2013-03-15 | 2020-04-30 | Cyclerion Therapeutics, Inc. | SGC stimulatorji |
| EP3092231B1 (de) | 2013-12-11 | 2018-06-27 | Ironwood Pharmaceuticals, Inc. | Sgc-stimulatoren |
| EP3094327A1 (de) | 2014-01-13 | 2016-11-23 | Ironwood Pharmaceuticals, Inc. | Verwendung von sgc-stimulatoren zur behandlung von neuromuskulären störungen |
| CA2939892C (en) | 2014-03-17 | 2020-03-31 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| CN106103437A (zh) | 2014-03-18 | 2016-11-09 | 埃科特莱茵药品有限公司 | 氮杂吲哚乙酸衍生物及其作为前列腺素d2受体调节剂的用途 |
| US20170298055A1 (en) | 2014-09-17 | 2017-10-19 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| CA2961489A1 (en) | 2014-09-17 | 2016-03-24 | Glen Robert RENNIE | Sgc stimulators |
| CA2959757A1 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | Pyrazole derivatives as sgc stimulators |
| CN108026093B (zh) | 2015-09-15 | 2021-11-16 | 爱杜西亚药品有限公司 | 结晶形式 |
| KR102513343B1 (ko) | 2016-07-07 | 2023-03-22 | 사이클리온 테라퓨틱스, 인크. | sGC 자극제의 인 전구약물 |
| BR112019000293A2 (pt) | 2016-07-07 | 2019-04-16 | Ironwood Pharmaceuticals, Inc. | formas sólidas de um estimulador de sgc |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5565473A (en) * | 1990-10-12 | 1996-10-15 | Merck Frosst Canada, Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
| ATE337294T1 (de) * | 1995-06-21 | 2006-09-15 | Shionogi & Co | Bizyklische aminoderivate und enthaltende pgd2- antagonisten |
| CA2274591C (en) * | 1996-12-13 | 2005-06-14 | Shionogi & Co., Ltd. | Benzothiophenecarboxamide derivatives and pgd2 antagonists comprising them |
-
2001
- 2001-04-09 AT AT01923433T patent/ATE311200T1/de not_active IP Right Cessation
- 2001-04-09 DE DE60115411T patent/DE60115411D1/de not_active Expired - Lifetime
- 2001-04-09 WO PCT/CA2001/000491 patent/WO2001078697A2/en not_active Ceased
- 2001-04-09 EP EP01923433A patent/EP1274457B1/de not_active Expired - Lifetime
- 2001-04-09 JP JP2001575998A patent/JP2003530426A/ja not_active Withdrawn
- 2001-04-09 AU AU2001250206A patent/AU2001250206A1/en not_active Abandoned
- 2001-04-09 CA CA002405233A patent/CA2405233A1/en not_active Abandoned
- 2001-04-09 US US10/239,717 patent/US20030055077A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20030055077A1 (en) | 2003-03-20 |
| EP1274457B1 (de) | 2005-11-30 |
| EP1274457A2 (de) | 2003-01-15 |
| JP2003530426A (ja) | 2003-10-14 |
| CA2405233A1 (en) | 2001-10-25 |
| AU2001250206A1 (en) | 2001-10-30 |
| DE60115411D1 (de) | 2006-01-05 |
| WO2001078697A3 (en) | 2002-08-01 |
| WO2001078697A2 (en) | 2001-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60115411D1 (de) | Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten | |
| ATE293989T1 (de) | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten | |
| DE60140377D1 (de) | Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit | |
| ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| DE60204548D1 (de) | Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit | |
| DE60135029D1 (de) | Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis | |
| ATE515513T1 (de) | Behandlung von fibrose durch antagonismus zwischen il-13 und il-13-rezeptorketten | |
| EP1156792A4 (de) | Methoden und zusammenstellungen zur behandlung des reizdarmsyndroms unter verwendung von niedrigdosierten antagonisten des opioidrezeptors | |
| DE60228567D1 (de) | Behandlung von hyperlipidämie | |
| ATE328879T1 (de) | Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv | |
| DE69528475D1 (de) | Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie | |
| DE60228073D1 (de) | Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen | |
| DE60124666D1 (de) | Verfahren zur hydrierung von conjugierten dienpolymeren und copolymeren | |
| EA200400734A1 (ru) | Способ и композиция для потенциирования действия опиатного анальгетика | |
| ATE381938T1 (de) | Verwendungen zur behandlung von fsh-verbundenen zuständen mit gnrh antagonisten | |
| ATE371454T1 (de) | Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie | |
| DE60114027D1 (de) | Verwendung von einem aldosteron-rezeptor-antagonisten zur verbesserung der kognitiven funktion | |
| DE60136748D1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen | |
| ATE352038T1 (de) | Kit und verfahren zum nachweis von fäkalen parasiten | |
| ATE317268T1 (de) | Verwendung eines h1-antagonisten und von rimexolon als sicheres steroid zur behandlung von rhinitis | |
| ATE385789T1 (de) | Verwendung von einem aldosteronantagonist zur behandlung und vorbeugung von aldosteron- vermittelten pathogenen zuständen | |
| ATE359816T1 (de) | Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren | |
| DE60221275D1 (de) | Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma | |
| ATE255094T1 (de) | Piperazinderivate zur behandlung der niedrigen harnwege | |
| HRP20050572A2 (en) | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |